OBJECTIVES: To evaluate health utilities at different stages of RRMS. METHODS: In two studies OPERA I & II (Hauser et al. 2015) 1’656 RRMS patients were randomized to treatment with ocrelizumab 600mg or interferon β-1a 44ug. Expanded Disability Status Scale (EDSS) states and EQ5D were assessed at baseline, 48 and 96 weeks. The relationship between EDSS and EQ5D was investigated through a repeated measures linear model that regressed health utilities on EDSS states, sex, age, relapse within 30 days prior to assessment and region of the world. RESULTS: Health utilities were found to be inversely associated with EDSS state: the higher the EDSS state, the lower the utility score. The average health utility for a 75% female, ex-US population, aged 51, having not experienced a relapse in the 30 days prior to assessment was found to be 0.88 (95%CI: 0.85-0.91) for EDSS 0; 0.84 (95%CI: 0.83-0.86) for EDSS 1; 0.77 (95%CI:0.76-0.78) for EDSS 2; 0.70 (95%CI:0.69-0.72) for EDSS 3; 0.64 (95%CI: 0.63-0.66) for EDSS 4; 0.60 (95%CI: 0.57-0.63) for EDSS 5; 0.49 (95%CI: 0.45-0.53) for EDSS 6 and 0.44 (95%CI:0.24-0.63) for EDSS 7. No state beyond 7 was observed in the 96 week trial period. After adjustment for EDSS state, utilities were further associated with relapse (-0.10, p<0.0001), age (-0.01 per 10 years, p=0.0335), female sex (-0.03, p=0.006) and US region (-0.05, p<0.0001). CONCLUSIONS: In the absence of generic quality of health measures, health utilities can be derived based on EDSS state, gender, age, region of the world and relapse. These results are comparable with previous published data (Orme et al. 2007).